Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426196 | 0.93 | MMP13 (0.63) | MMP13PDPK1 | |
| SCHEMBL5696853 | 0.83 | MMP13 (0.73) | MMP13PDPK1 | |
| SCHEMBL6298027 | 0.82 | MMP13 (0.81) | MMP13PDPK1 | |
| SCHEMBL5696937 | 0.77 | MMP13 (0.78) | MMP13PDPK1 | |
| SCHEMBL30573507 | 0.76 | GRK2 (0.48) | MMP13PDPK1 | |
| SCHEMBL5697278 | 0.75 | MMP13 (0.79) | MMP13PDPK1 | |
| SCHEMBL6663871 | 0.74 | MMP13 (0.63) | MMP13PDPK1 | |
| SCHEMBL6297360 | 0.73 | MMP13 (0.85) | MMP13 | |
| SCHEMBL6302790 | 0.72 | MMP13 (0.69) | MMP13PDPK1 | |
| SCHEMBL6297353 | 0.72 | MMP13 (1.00) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | claimed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6894057-B2 | Oxo-azabicyclic compounds | WARNER-LAMBERT COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6747147-B2 | INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER | WARNER-LAMBERT COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | MMP13 1/4885PDPK1 4673/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | MMP13 1/4885PDPK1 2000/4885 |
| US-20030220355-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, CA13 | MMP13 1/4885PDPK1 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.